Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Clinical Trials

Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Registration Number: NCT00005051

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
Saint Vincent Catholic Medical Center of New York, New York, New York, United States
🇺🇸
New York Hospital Medical Center of Queens, Fresh Meadows, New York, United States

and more 7 locations

Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Phase 3

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 400

Registration Number: NCT00003945

Locations: 🇺🇸
Mercy Cancer Center at Mercy Medical Center-Des Moines, Des Moines, Iowa, United States
🇺🇸
John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 8 locations

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: isotretinoin
Drug: melphalan
Drug: topotecan hydrochloride
Drug: vincristine sulfate
Procedure: autologous bone marrow transplantation
Procedure: bone marrow ablation with stem cell support
Procedure: conventional surgery
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-17

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 495

Registration Number: NCT00004188

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 93 locations

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2021-09-09

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 14

Registration Number: NCT00025272

Locations: 🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States
🇺🇸
Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States
🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

and more 2 locations

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: etoposide
Drug: ifosfamide
Drug: topotecan hydrochloride
Procedure: autologous bone marrow transplantation
Drug: Mesna

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT00006373

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 1

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: 7-hydroxystaurosporine
Drug: topotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2016-06-23

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 33

Registration Number: NCT00045175

Locations: 🇨🇦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada